Popular Articles

Swissmedic Grants Debiopharm Marketing Authorisation For Moapar(R), A New Therapeutic Avenue For The Treatment Of Sexual Deviations
Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announced that the Swiss agency for therapeutic products, Swissmedic, has issued a marketing authorisation for Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue.
drugs without prescription
Numbers Of People With MS Higher Than Previously Estimated
New research released by the MS Society has for the first time revealed an accurate estimate of the number of people living with a diagnosis of multiple sclerosis (MS) in the UK.
News of the day
Expert Group To Review Pharmacy Services In Wales
An expert group has been set up to review pharmacy services across Wales as part of the Welsh Assembly Government"s commitment to develop community pharmacy services and pharmacy-based drop-in centres.
Endocrinology

Abdominal Massage Shown To Benefit Constipation In MS

Trail results have highlighted the benefit of abdominal massage in the management of constipation - a common symptom in people with multiple sclerosis (MS). In the latest study, reporting in the International Journal of Nursing Studies, 60 people with constipation were split into two groups and given a combination of laxatives and abdominal massage, or were given laxatives alone for eight weeks. It was found that the group of people being treated with a combination of laxatives and abdominal massage had reduced severity of abdominal symptoms, including constipation and pain, than the group taking laxatives alone. The MS Society has recognised the importance of finding new ways to manage common MS symptoms such as constipation. Last year more than ÷£120,000 was spent on a project to help develop a better approach to managing a variety of bowel syndromes for people with MS and formed part of the MS Society"s Symptom Relief Research Initiative. MS Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):